menu search

RETA / Reata Pharmaceuticals, Inc. (RETA) Q1 2023 Earnings Call Transcript

Reata Pharmaceuticals, Inc. (RETA) Q1 2023 Earnings Call Transcript
Reata Pharmaceuticals, Inc. (NASDAQ:RETA ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Warren Huff - Chairman and Chief Executive Officer Dawn Bir - Executive Vice President and Chief Commercial Officer Andrea Loewen - Senior Vice President of Global Regulatory Affairs Seemi Khan - Senior Vice President and Chief Medical Officer Colin Meyer - Executive Vice President and Chief Innovation Officer Manmeet Soni - President, Chief Operating Officer and Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Kumar - Goldman Sachs Yatin Suneja - Guggenheim Securities Charles Duncan - Cantor Fitzgerald Carter Gould - Barclays Annabel Samimy - Stifel Maury Raycroft - Jefferies Matthew Kaplan - Ladenburg Thalmann Operator Thank you for standing by, and welcome to the Reata Pharmaceuticals First Quarter Financial Results Update on Operational Progress and Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call in the Investor section of Reata's website at reatapharma.com. Read More
Posted: May 11 2023, 00:04
Author Name: Seeking Alpha
Views: 082179

RETA News  

CPMG Inc Acquires Significant Stake in Reata Pharmaceuticals Inc

By GuruFocus
August 1, 2023

CPMG Inc Acquires Significant Stake in Reata Pharmaceuticals Inc

CPMG Inc (Trades, Portfolio), a prominent investment firm, recently expanded its portfolio with the acquisition of a substantial number of shares in R more_horizontal

Reata Pharmaceuticals stock opened 50% up on Friday: what happened?

By Invezz
July 28, 2023

Reata Pharmaceuticals stock opened 50% up on Friday: what happened?

Shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) opened more than 50% up this morning after Biogen Inc (NASDAQ: BIIB) said it will buy the pharma co more_horizontal

Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?

By InvestorPlace
July 28, 2023

Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?

Reata Pharmaceuticals (NASDAQ: RETA ) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (NASDAQ: BIIB ). That de more_horizontal

Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last?

By Zacks Investment Research
June 29, 2023

Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last?

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate more_horizontal

Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS

By Zacks Investment Research
June 19, 2023

Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS

Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release. more_horizontal

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 6.9% Since Last Earnings Report?

By Zacks Investment Research
June 9, 2023

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 6.9% Since Last Earnings Report?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? more_horizontal

Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

By Business Wire
June 6, 2023

Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global more_horizontal

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

By Zacks Investment Research
May 11, 2023

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney more_horizontal


Search within

Pages Search Results: